Search Results

You are looking at 1 - 10 of 130 items for :

  • "hepatocellular carcinoma" x
Clear All
Full access

Amit G. Singal, Jorge A. Marrero and Adam Yopp

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and one of the leading causes of death among patients with cirrhosis. It has an increasing incidence in the United States because of the current epidemics

Full access

Kuan-Ling Kuo, David Stenehjem, Frederick Albright, Saurabh Ray and Diana Brixner

Background Hepatocellular carcinoma (HCC) is a primary malignancy of the liver. The American Cancer Society estimates that 33,190 new cases for primary liver cancer and intrahepatic bile duct cancer were diagnosed in 2014 in the United States

Full access

Jean F. Botha and Alan N. Langnas

. 3. Penn I . Hepatic transplantation for primary and metastatic cancers of the liver . Surgery 1991 ; 110 : 726 – 735 . 4. Iwatsuki S Starzl TE Sheahan DG . Hepatic resection versus transplantation for hepatocellular carcinoma

Full access

Ghassan K. Abou-Alfa

Treatment of Unresectable Hepatocellular Carcinoma . Available at: http://www.fda.gov/CDER/Offices/OODP/whatsnew/sorafenib.htm . Accessed February 9, 2009 . 2 Llovet JM Ricci S Mazzaferro V . Sorafenib in advanced hepatocellular carcinoma . N

Full access

Anne M. Covey

. Because the lesion is <10 mm, it is below the threshold for CT or MR. Thus, follow-up US in 3 to 6 months is recommended. (C) A hyperechoic liver mass >10 mm is suspicious for hepatocellular carcinoma and warrants further evaluation with multiphase CT or

Full access

Ju Dong Yang, Michael Luu, Amit G. Singal, Mazen Noureddin, Alexander Kuo, Walid S. Ayoub, Vinay Sundaram, Honore Kotler, Irene K. Kim, Tsuyoshi Todo, Georgios Voidonikolas, Todd V. Brennan, Kambiz Kosari, Andrew S. Klein, Andrew Hendifar, Shelly C. Lu, Nicholas N. Nissen and Jun Gong

Background A unifocal hepatocellular carcinoma (HCC) measuring <2 cm (T1 HCC) without vascular invasion and extrahepatic metastasis is the tumor-related component of very early-stage disease. 1 This stage of HCC has a decreased likelihood of

Full access

Andrew M. Moon, Hanna K. Sanoff, YunKyung Chang, Jennifer L. Lund, A. Sidney Barritt IV, Paul H. Hayashi and Karyn B. Stitzenberg

Background Hepatocellular carcinoma (HCC) incidence and mortality are increasing in the United States. 1 , 2 The prognosis for HCC is poor, in part because potentially curative treatments, including surgical resection, ablation, and transplantation

Full access

Caitlin A. Hester, Nicole E. Rich, Amit G. Singal and Adam C. Yopp

-related liver disease; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis. Clinicopathologic Features Table 1 describes the differences in clinicopathologic features among included patients

Full access

James J. Harding, Ghaith Abu-Zeinah, Joanne F. Chou, Dwight Hall Owen, Michele Ly, Maeve Aine Lowery, Marinela Capanu, Richard Do, Nancy E. Kemeny, Eileen M. O'Reilly, Leonard B. Saltz and Ghassan K. Abou-Alfa

Bone metastases are common in hepatocellular carcinoma (HCC), occurring in 25.5% to 38.5% of patients with extrahepatic disease. 1 – 5 As such, major practice guidelines, including those of NCCN, acknowledge the need to evaluate for HCC bone

Full access

Ali Mokdad, Travis Browning, John C. Mansour, Hao Zhu, Amit G. Singal and Adam C. Yopp

transition from hepatocellular carcinoma (HCC) diagnosis to treatment is a complex process involving multiple steps and providers from a multitude of specialties. Unlike many solid organ cancers, HCC is not diagnosed based on tissue biopsy results but rather